 |
August 15, 2008
Paths
to Progress: MS Focus Magazine features MRF update on myelin repair
research.
biotechTransfer week: Myelin Repair Foundation Taps CDD Software To Support ‘Accelerated’ Academic
Research
John Hagel and John Seely Brown review MRF’s ARC model in BusinessWeek’s Innovation
on the Edge.
Non-Profit Gears Up for Biotech
Roadshow
San Francisco Chronicle – March 29, 2008
“Johnson (MRF) has duplicated the collaborative environment Genentech
and other science-driven companies try to create for their in-house
researchers. Genentech wouldn't hesitate to hear proposals from the
nonprofit.” —Hal Barron, Senior Vice President of Development, Genentech
MRF Names Six Senior Pharma
Execs to Drug Discovery Advisory
Group (DDAG). The DDAG is tasked with evaluating and prioritizing MRF’s
therapeutic targets for myelin repair. Their input in the development
of industry-competitive data packages will be central to speeding MRF’s
drug discovery and development efforts. More…
Download a PDF version of the MRF brochure here.
|
|
August 11, 2008
 The ARC Model and Peer Review
When we launched our myelin repair research program four years ago, we developed
a rigorous peer review process to ensure that the science conducted in our
funded laboratories was of the highest quality, and that all experiments in
the program would lead us on the path of achieving (1) our interim goal of
licensing a myelin repair therapeutic target for commercial drug development
within five years and (2) our ultimate goal of making effective myelin repair
treatments available to MS patients.
Read more...
The objective of our multiple sclerosis research is to gain a deeper
understanding of the natural process of myelination and how multiple
sclerosis disrupts it. Through our research we are identifying therapeutic
targets that may restore the myelination process and effectively remyelinate
previously damaged areas in multiple sclerosis patients. Read
more about our multiple
sclerosis research. Register to receive research updates.
MRF depends on the support of individuals like you as well as corporations
and foundations, including the Robert Wood Johnson Foundation, Omidyar
Network and Biogen Idec, to name a few.
Donate now to myelin repair research
and MRF's accelerated research model. |
